Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Capital Expenditures (2016 - 2025)

Haemonetics has reported Capital Expenditures over the past 17 years, most recently at $6.3 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $6.3 million for Q4 2025, down 25.71% from a year ago — trailing twelve months through Dec 2025 was $30.8 million (up 1.46% YoY), and the annual figure for FY2025 was $39.3 million, up 3.02%.
  • Capital Expenditures for Q4 2025 was $6.3 million at Haemonetics, up from $5.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for HAE hit a ceiling of $93.1 million in Q2 2023 and a floor of $3.8 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $12.8 million (2021), compared with a mean of $19.6 million.
  • Biggest five-year swings in Capital Expenditures: soared 226.65% in 2022 and later tumbled 92.82% in 2024.
  • Haemonetics' Capital Expenditures stood at $20.8 million in 2021, then dropped by 19.05% to $16.8 million in 2022, then decreased by 13.07% to $14.6 million in 2023, then crashed by 41.65% to $8.5 million in 2024, then decreased by 25.71% to $6.3 million in 2025.
  • The last three reported values for Capital Expenditures were $6.3 million (Q4 2025), $5.0 million (Q3 2025), and $3.8 million (Q2 2025) per Business Quant data.